Literature DB >> 14703116

Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues.

H J Kim1, H Z Chae, Y J Kim, Y H Kim, T S Hwangs, E M Park, Y M Park.   

Abstract

Transient/chronic microenvironmental hypoxia that exists within a majority of solid tumors has been suggested to have a profound influence on tumor growth and therapeutic outcome. Since the functions of novel antioxidant proteins, peroxiredoxin I (Prx I) and II, have been implicated in regulating cell proliferation, differentiation, and apoptosis, it was of our special interest to probe a possible role of Prx I and II in the context of hypoxic tumor microenvironment. Since both Prx I and II use thioredoxin (Trx) as an electron donor and Trx is a substrate for thioredoxin reductase (TrxR), we investigated the regulation of Trx and TrxR as well as Prx expression following hypoxia. Here we show a dynamic change of glutathione homeostasis in lung cancer A549 cells and an up-regulation of Prx I and Trx following hypoxia. Western blot analysis of 10 human lung cancer and paired normal lung tissues also revealed an elevated expression of Prx I and Trx proteins in lung cancer tissues. Immunohistochemical analysis of the lung cancer tissues confirmed an augmented Prx I and Trx expression in cancer cells with respect to the parenchymal cells in adjacent normal lung tissue. Based on these results, we suggest that the redox changes in lung tumor microenvironment could have acted as a trigger for the up-regulation of Prx I and Trx in lung cancer cells. Although the clinical significance of our finding awaits more rigorous future study, preferential augmentation of the Prx I and Trx in lung cancer cells may well represent an attempt of cancer cells to manipulate a dynamic redox change in tumor microenvironment in a manner that is beneficial for their proliferation and malignant progression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14703116     DOI: 10.1023/b:cbto.0000004952.07979.3d

Source DB:  PubMed          Journal:  Cell Biol Toxicol        ISSN: 0742-2091            Impact factor:   6.691


  31 in total

1.  Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.

Authors:  Chul-Kee Park; Jin Hyun Kim; Min Jeong Moon; Ji Hye Jung; Su-Young Lim; Sung-Hye Park; Jong-Hoon Kim; Dong Gyu Kim; Hee-Won Jung; Byung-Kyu Cho; Sun Ha Paek
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-26       Impact factor: 4.553

Review 2.  Redox-based regulation of signal transduction: principles, pitfalls, and promises.

Authors:  Yvonne M W Janssen-Heininger; Brooke T Mossman; Nicholas H Heintz; Henry J Forman; Balaraman Kalyanaraman; Toren Finkel; Jonathan S Stamler; Sue Goo Rhee; Albert van der Vliet
Journal:  Free Radic Biol Med       Date:  2008-03-27       Impact factor: 7.376

3.  Aberrant expression of peroxiredoxin 1 and its clinical implications in liver cancer.

Authors:  Yu-Lin Sun; Jian-Qiang Cai; Fang Liu; Xin-Yu Bi; Lan-Ping Zhou; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature.

Authors:  Jonah R Riddell; Wiam Bshara; Michael T Moser; Joseph A Spernyak; Barbara A Foster; Sandra O Gollnick
Journal:  Cancer Res       Date:  2011-02-22       Impact factor: 12.701

5.  Activation of hypoxia-inducible factor-1 protects airway epithelium against oxidant-induced barrier dysfunction.

Authors:  Nels Olson; Milena Hristova; Nicholas H Heintz; Karen M Lounsbury; Albert van der Vliet
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-16       Impact factor: 5.464

6.  Expression of peroxiredoxin 1 and 4 promotes human lung cancer malignancy.

Authors:  Hong Jiang; Lisha Wu; Murli Mishra; Hedy A Chawsheen; Qiou Wei
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

Review 7.  Peroxiredoxins and Beyond; Redox Systems Regulating Lung Physiology and Disease.

Authors:  Evan A Elko; Brian Cunniff; David J Seward; Shi Biao Chia; Reem Aboushousha; Cheryl van de Wetering; Jos van der Velden; Allison Manuel; Arti Shukla; Nicholas H Heintz; Vikas Anathy; Albert van der Vliet; Yvonne M W Janssen-Heininger
Journal:  Antioxid Redox Signal       Date:  2019-04-05       Impact factor: 8.401

8.  Peroxiredoxin 1 stimulates secretion of proinflammatory cytokines by binding to TLR4.

Authors:  Jonah R Riddell; Xiang-Yang Wang; Hans Minderman; Sandra O Gollnick
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

9.  Nuclear expression of thioredoxin-1 in the invasion front is associated with outcome in patients with gallbladder carcinoma.

Authors:  Motoaki Nagano; Kinta Hatakeyama; Masahiro Kai; Hajime Nakamura; Junji Yodoi; Yujiro Asada; Kazuo Chijiiwa
Journal:  HPB (Oxford)       Date:  2012-06-08       Impact factor: 3.647

10.  Prx I suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/cyclin D1 pathway.

Authors:  Young-Ho Park; Sun-Uk Kim; Bo-Kyoung Lee; Hyun-Sun Kim; In-Sung Song; Hye-Jun Shin; Ying-Hao Han; Kyu-Tae Chang; Jin-Man Kim; Dong-Seok Lee; Yeul-Hong Kim; Chang-Min Choi; Bo-Yeon Kim; Dae-Yeul Yu
Journal:  Antioxid Redox Signal       Date:  2013-06-13       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.